There were 601 press releases posted in the last 24 hours and 150,739 in the last 365 days.

BDA International Release: Co-Diagnostics Adds Central and South America to its List of International Markets

BARCELONA, CATALUNYA, SPAIN, September 13, 2018 / -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, today announced that it is in process of expanding its list of international target markets with the completion of a trip to interested laboratories and future sales installations across Central America. As the Company approaches imminent commercialization of selected molecular diagnostic tests, Latin America joins India and the Caribbean region as important target markets for its products.

According to the Company, the purpose of the trip was to introduce Co-Diagnostics’ products to some of the establishments that have expressed interest in their infectious disease detection platform, including the Company’s CE-IVD tuberculosis test, as well other tests for human papillomavirus, Zika virus, hepatitis B virus, and a viral load test for hepatitis B .

The trip and product demonstrations were conducted by local Company representatives and Cameron Gundry, Co-Diagnostics’ recently-appointed Director of Commercialization for Latin America. Mr. Gundry, a veteran of the industry including 18 years with Biofire Diagnostics, commented upon his return, “Tuberculosis, human papillomavirus, Zika and hepatitis B are significant issues throughout Latin America. After several years of product development and market-research to determine demand, this trip represented an important phase in our efforts to bring Co-Diagnostics’ products to the Latin American region.

“The Company has long believed that interest levels would be high for our quality, affordable diagnostics, and the feedback we received from the cross-section of potential customers we had the fortune of visiting, some of which were among the largest laboratories of their kind in those countries, confirmed our beliefs. We feel confident that the groundwork we are laying has the potential to result in a substantial ROI for the Company.”

Co-Diagnostics’ products are sold in compliance with the local registration and regulatory requirements of the importing countries, including offering products through regional distributors where available. The Company expects sales to commence once those requirements have been met, and for products to be available as in-vitro diagnostics following approvals by the appropriate regulatory bodies.

You can read more about the Company at the Wall Street Club.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide strategic action plans, and investor/market perception studies to help entities improve communication with customers and investors and increase their visibility.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Mushtaq Dost
BDA International Investor Relations
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.